Related Experiment Videos

CA-125 is not a useful marker in metastatic breast cancer

M J Seckl¹, G J Rustin, R C Coombes

¹Department of Medical Oncology, CRC Laboratories, Charing Cross Hospital, London, UK.

British Journal of Cancer

|November 1, 1992

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Demographics of epithelioid trophoblastic tumour and placental site trophoblastic tumour: a 21 year UK population study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2025

Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature.

Gynecologic oncology reports·2023

Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report.

Gynecologic oncology reports·2023

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Nature communications·2022

Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate.

Gynecologic oncology reports·2021

Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.

ESMO open·2021

See all related articles